Division of Nephrology, University of Alberta, Edmonton, Alberta, Canada.
Am J Kidney Dis. 2010 May;55(5):875-84. doi: 10.1053/j.ajkd.2009.12.038. Epub 2010 Mar 25.
It is controversial whether tighter glycemic control is associated with better clinical outcomes in people with kidney failure. We aim to determine whether worse glycemic control, measured using serum glucose and hemoglobin A(1c) (HbA(1c)) levels, is independently associated with higher mortality in patients undergoing maintenance hemodialysis.
Retrospective cohort study.
SETTING & PARTICIPANTS: 1,484 patients starting maintenance hemodialysis therapy in Alberta, Canada, between 2001 and 2007.
Serum glucose and HbA(1c) levels.
All-cause mortality.
Monthly casual glucose levels from specimens drawn immediately before the first dialysis treatment were averaged over 3 months before and after hemodialysis therapy initiation. Similarly, monthly HbA(1c) values in patients with or at risk of diabetes were averaged.
Overall, median age was 66 years, 41% were women, 75% were white, and 55% had diabetes. All-cause mortality during 8 years (median, 1.5 years) was 43%; it was 49% in those with diabetes. There was no relation between average glucose level and mortality in unadjusted analysis (HR, 1.00 per 18 mg/dL [1 mmol/L]; P = 0.4) or after adjustment for confounders (HR, 0.98 per 18 mg/dL; 95% CI, 0.96-1.01; P = 0.2). Higher HbA(1c) level was not associated with mortality when analyzed in the unadjusted analysis (HR, 1.01 per 1% HbA(1c); P = 0.9) or after adjustment for confounders (HR, 0.98 per 1% HbA1c; 95% CI, 0.88-1.08; P = 0.7). Results were similar when HbA(1c) values were divided into prespecified categories (adjusted P > 0.6 for trend). Markers of malnutrition-inflammation (albumin, hemoglobin, and white blood cell values) or the presence of diabetes did not influence the relation between glycemic control and death (all P for interaction > 0.2).
Registry data; casual serum glucose measurements; HbA(1c) values available for only a subset of participants.
Higher casual glucose and HbA(1c) levels were not associated with mortality in maintenance hemodialysis patients with or without diabetes. This may have implications for recommended glycemic targets, quality indicators, and how best to assess glycemic control in this high-risk population.
在肾衰竭患者中,血糖控制更严格是否与更好的临床结局相关仍存在争议。我们旨在确定在接受维持性血液透析的患者中,使用血清葡萄糖和糖化血红蛋白(HbA(1c))水平衡量的血糖控制较差是否与死亡率升高独立相关。
回顾性队列研究。
2001 年至 2007 年间,在加拿大艾伯塔省开始维持性血液透析治疗的 1484 名患者。
血清葡萄糖和 HbA(1c)水平。
全因死亡率。
在开始血液透析治疗前立即采集的标本中每月的随机血糖水平,在血液透析治疗开始前 3 个月内进行平均。同样,对有或有糖尿病风险的患者的每月 HbA(1c)值进行平均。
总体而言,中位年龄为 66 岁,41%为女性,75%为白人,55%患有糖尿病。8 年(中位 1.5 年)期间的全因死亡率为 43%;糖尿病患者的死亡率为 49%。未经调整分析(每 18mg/dL[1mmol/L]增加 1.00 的 HR;P=0.4)或调整混杂因素后(每 18mg/dL 增加 0.98;95%CI,0.96-1.01;P=0.2),平均血糖水平与死亡率之间没有关系。未经调整分析(每 1%HbA(1c)增加 1.01 的 HR;P=0.9)或调整混杂因素后(每 1%HbA1c 增加 0.98 的 HR;95%CI,0.88-1.08;P=0.7),HbA(1c)水平较高与死亡率无关。当 HbA(1c)值分为预设类别时,结果相似(趋势的调整 P>0.6)。营养不良-炎症标志物(白蛋白、血红蛋白和白细胞值)或糖尿病的存在并未影响血糖控制与死亡之间的关系(所有交互 P>0.2)。
登记数据;随机血清葡萄糖测量;仅部分参与者有 HbA(1c) 值。
在有或没有糖尿病的维持性血液透析患者中,较高的随机血糖和 HbA(1c)水平与死亡率无关。这可能对推荐的血糖目标、质量指标以及如何最好地评估该高危人群的血糖控制产生影响。